www.qxeyes.com
The use of tamsulosin within 14 days of cataract surgery has been associated with serious postoperative problems, according to an article published in the Journal of the American Medical Association . X
tamsulosin in alpha-adrenergic blocker that has been commonly prescribed to treat benign prostatic hyperplasia, and which has been described that increases the risk of intraoperative complications during cataract surgery. But until recently were not described the potential postoperative complications after use of tamsulosin versus other alpha-blockers used in the treatment of prostate disease. X
The paper has compared the complications between patients treated with tamsulosin versus other alpha-blockers, and the existence of recent exposure to tamsulosin (14 days prior) or from 15 to 365 days earlier, on a set of 3550 patients treated with tamsulosin and 7426 treaties with other alpha-blockers. X
adverse effects have been reported in 284 patients (0.3%), including 100 cases of suspected endophthalmitis, 175 cases of detention crystal fragments, 35 detachments and 26 cases of retinal detachment and retention of fragments. These effects were not observed with the use of other alpha-blockers. X
The study concludes that "exposure to tamsulosin in the 14 days prior to cataract surgery has been shown related to increased incidence of serious postoperative complications eye, whereas no association was found with other alpha-blockers used to treat benign prostatic hypertrophy.
X
Since the combination of cataract surgery and treatment with tamsulosin is relatively common for patients should be warned of potential risks, and the ophthalmologist must plan and schedule the surgery as compared to potential intraoperative complications (floppy iris syndrome) and postoperative. To this end, different strategies have been proposed as strong cycloplegic dilation (atropine or homatropine), high density viscoelastic agents, low flow intraoperative use of iris retractors or other stabilization procedures or pupillary dilation.
X
JAMA. 2009; 301:1991-1996, 2044-2045. X
Basic information and guidance. To personalized information consult your ophthalmologist.
x
CEUTA EYES. INNOVATION IN OPHTHALMOLOGY.
EYE CENTER DR. CATOIRA MEDIN
tamsulosin in alpha-adrenergic blocker that has been commonly prescribed to treat benign prostatic hyperplasia, and which has been described that increases the risk of intraoperative complications during cataract surgery. But until recently were not described the potential postoperative complications after use of tamsulosin versus other alpha-blockers used in the treatment of prostate disease. X
The paper has compared the complications between patients treated with tamsulosin versus other alpha-blockers, and the existence of recent exposure to tamsulosin (14 days prior) or from 15 to 365 days earlier, on a set of 3550 patients treated with tamsulosin and 7426 treaties with other alpha-blockers. X
adverse effects have been reported in 284 patients (0.3%), including 100 cases of suspected endophthalmitis, 175 cases of detention crystal fragments, 35 detachments and 26 cases of retinal detachment and retention of fragments. These effects were not observed with the use of other alpha-blockers. X
The study concludes that "exposure to tamsulosin in the 14 days prior to cataract surgery has been shown related to increased incidence of serious postoperative complications eye, whereas no association was found with other alpha-blockers used to treat benign prostatic hypertrophy.
X
Since the combination of cataract surgery and treatment with tamsulosin is relatively common for patients should be warned of potential risks, and the ophthalmologist must plan and schedule the surgery as compared to potential intraoperative complications (floppy iris syndrome) and postoperative. To this end, different strategies have been proposed as strong cycloplegic dilation (atropine or homatropine), high density viscoelastic agents, low flow intraoperative use of iris retractors or other stabilization procedures or pupillary dilation.
X
JAMA. 2009; 301:1991-1996, 2044-2045. X
Basic information and guidance. To personalized information consult your ophthalmologist.
x
CEUTA EYES. INNOVATION IN OPHTHALMOLOGY.
EYE CENTER DR. CATOIRA MEDIN
Eyes Ceuta - Innovating Ophthalmology Ophthalmology Center Dr. MedÃn Catoira 
0 comments:
Post a Comment